TAK vs. VTRS: Takeda Pharmaceutical vs. Viatris Stock Comparison

Company Profile

Takeda Pharmaceutical (TAK) and Viatris (VTRS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Viatris (VTRS) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Viatris (VTRS) has a non-negative beta of 0.86.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Takeda Pharmaceutical (TAK) reports 0.56%, ranking against industry peers normally.

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Takeda Pharmaceutical (TAK) reports 0.87%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) at 24.55% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Takeda Pharmaceutical (TAK) at -1.66% and Viatris (VTRS) at -2.98% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Only one side can be read here: Takeda Pharmaceutical (TAK) reports EPS growth of 77.96%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Takeda Pharmaceutical (TAK) at 1.15 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Takeda Pharmaceutical (TAK) at 0.72 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Both Takeda Pharmaceutical (TAK) at 953.28% and Viatris (VTRS) at 2.53% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Takeda Pharmaceutical (TAK) at 426.53% and Viatris (VTRS) at 960.00% report payout ratio above 100%, meaning dividends exceeded current-period earnings on both sides.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Takeda Pharmaceutical (TAK) trades at 300.29 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

Both Takeda Pharmaceutical (TAK) at 0.01 and Viatris (VTRS) at 1.55 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

Relative to net asset value, both Takeda Pharmaceutical (TAK) at 1.43 and Viatris (VTRS) at 1.67 look inexpensive, sitting in the lower P/B ratio quartile of their industries.

Valuation Metrics